Evidence map›Paper›PMID 40514435›Full record

Trial reportNature cardiovascular research2025

Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarction.

Rahul Aggarwal, Deepak L Bhatt, Adrian F Hernandez, Stefan D Anker, Josephine Harrington, W Schuyler Jones, Michaela Mattheus, Mark C Petrie, Dominik Steubl, Mikhail Sumin and 3 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Nature cardiovascular research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Rahul AggarwalBrigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.
Deepak L BhattMount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY, USA. DLBhattMD@post.Harvard.edu.ORCID http://orcid.org/0000-0002-1278-6245
Adrian F HernandezDuke University Department of Medicine, Division of Cardiology, and Duke Clinical Research Institute, Durham, NC, USA.
Stefan D AnkerDepartment of Cardiology (CVK) of German Heart Center Charité, Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.ORCID http://orcid.org/0000-0002-0805-8683
Josephine HarringtonDuke University Department of Medicine, Division of Cardiology, and Duke Clinical Research Institute, Durham, NC, USA.
W Schuyler JonesDuke University Department of Medicine, Division of Cardiology, and Duke Clinical Research Institute, Durham, NC, USA.
Michaela MattheusBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Mark C PetrieSchool of Cardiovascular and Medical Sciences, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0002-6333-9496
Dominik SteublDepartment of Nephrology, Hospital rechts der Isar, Technical University Munich, Munich, Germany.
Mikhail SuminBoehringer Ingelheim International GmbH, Ingelheim, Germany.ORCID http://orcid.org/0000-0002-3827-5793
Vikram ThanamBoehringer Ingelheim International GmbH, Ingelheim, Germany.
Jacob A UdellWomen's College Hospital and Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
Javed ButlerBaylor Scott and White Research Institute, Dallas, TX, USA.ORCID http://orcid.org/0000-0001-7683-4720

Funding

TRAINING PROGRAM IN CARDIOVASCULAR RESEARCHT32HL007604 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MARK W FEINBERG · 1985 to 2026
$19.0M
NHLBI NIH HHS T32 HL007604
6 · The paper itself

Abstract

Data on the cardiovascular-kidney effects and safety of empagliflozin among patients with acute myocardial infarction are limited. EMPACT-MI (Study to Evaluate the Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients with Acute Myocardial Infarction) was a double-blind, multicenter clinical trial that randomized 6,522 patients with acute myocardial infarction and risk for heart failure to empagliflozin or placebo. Here we show in this secondary analysis that the mean estimated glomerular filtration rate at baseline was 76.1 ml min

Indexed as

Benzhydryl CompoundsGlomerular Filtration RateGlucosidesHeart FailureKidneyMyocardial InfarctionSodium-Glucose Transporter 2 InhibitorsAgedDouble-Blind MethodFemaleHumansMaleMiddle AgedTime FactorsTreatment OutcomeBenzhydryl CompoundsempagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID40514435
PMCPMC12170341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.